PURPOSE: A dramatic improvement in the survival of patients with chronic myeloid leukemia (CML) occurred after the introduction of imatinib mesylate, the first tyrosine kinase inhibitor (TKI). We assessed how these changes affected the life expectancy of patients with CML and life-years lost as a...
PURPOSE: A dramatic improvement in the survival of patients with chronic myeloid leukemia (CML) occurred after the introduction of imatinib mesylate, the first tyrosine kinase inhibitor (TKI). We assessed how these changes affected the life expectancy of patients with CML and life-yea...
Patients may also be placed on either a partial or complete mechanical system to support the heart. One of several partial systems, the Left Ventricular Assist Device, is passed through a groin artery to temporarily assume some of the heart's work until it can regain its ability to function ...
Patients taking imatinib for chronic myelogenous leukemia (CML) and who are in remission after two years of treatment have a mortality rate similar to that of the general population, according to a study published online in the .doi:10.1097/01.COT.0000397981.30782.fcNA...
ONLINE FIRST: CML Patients on Imatinib have Life Expectancy Similar to That of General PopulationStockwellSerena
Summary Studies on the conditional life expectancy of patients with chronic myeloid leukaemia (CML) are lacking. Using data from the Netherlands Cancer Registry, we examined the life expectancy of patients with CML in the Netherlands diagnosed during 1989–2018. As of the early 2010s, the life ...
Contrary to expectations, the Israeli cohort showed a shorter actual life expectancy than projected, suggesting a larger impact of CML on elderly survival. In summary, imatinib remains the main initial treatment, but second-generation TKIs are on the rise among elderly CML patients. Outcomes in ...
Introduction: Since the life expectancy of chronic phase chronic myeloid leukemia (CML) patients increased in the era of the tyrosine kinase inhibitors (TKIs), both the CML caring physicians and the patients face another important issue - quality of life (QoL). In daily clinical practice, in ...
Imatinib may give normal life expectancy to patients with CML.(just in)(chronic myelogenous leukemia)(Report)McBride, Deborah
Background With the advent of tyrosine kinase inhibitors (TKIs), patients with chronic myeloid leukemia (CML) have a life expectancy similar to those of age- and sex-matched healthy populations. Nevertheless, patients receiving TKIs report chronic adverse events such as fatigue, edema, and muscle ...